Biopharma
ByCan Pfizer’s 2025 Earnings Reignite Confidence in Its Post-COVID Portfolio and Late-Stage Pipeline?
Late January 2026 | Full-Year 2025 Earnings Preview | Big Pharma Strategy Reset Pfizer is set to report…
Will Novartis’ January 2026 Earnings Validate the Strength of Its Focused Portfolio and Late-Stage Pipeline?
January 30, 2026 | Full-Year 2025 Earnings Preview | Innovative Medicines Outlook Novartis is scheduled to report its…
Will Roche’s 2025 Earnings Reset the Narrative for 2026 Growth and Pipeline Confidence?
January 29, 2026 | Full-Year Earnings | Big Pharma Outlook Roche is set to publish its full-year 2025…
Why Is Roche Returning to China for Its Next Antibody-Drug Conjugate Bet?
January 2026 – Strategic Partnerships | China Biopharma | Oncology & ADCs Roche has extended its collaboration with…
What If HER2 Resistance Was Over? Henlius Doses First Patient in Phase 2/3 HLX22 Trial, Unleashing Multi-Oncology Disruption
Shanghai, China – March 3, 2026 – Henlius Biotech, Inc. (HKEX: 2696), a global biopharmaceutical leader in oncology innovation,…
BMS’s Chinese-Licensed ADC CC-1234 Delivers 52% ORR, 14-Month PFS in Aggressive HER2-Low Breast Cancer
Published by BioNextAI Media – Bristol Myers Squibb (NYSE: BMY) unveiled compelling Phase 2 data for CC-1234, its next-generation…
